Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

SAVE-PCI: Small-Bore Percutaneous VAD Matches IABP in High-risk PCI

News Conference News TCT 2025

SAVE-PCI: Small-Bore Percutaneous VAD Matches IABP in High-risk PCI

November 06, 2025

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions

News Conference News TCT 2025

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions

October 26, 2025

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

October 25, 2023

Disrupt CAD III Shows Sustained Benefit for Lithotripsy at 1 Year

News Conference News TCT 2021

Disrupt CAD III Shows Sustained Benefit for Lithotripsy at 1 Year

November 05, 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

News Conference News TCT 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

Yael L. Maxwell

November 05, 2021

iFR Matches FFR Through 5 Years: iFR-SWEDEHEART

News Conference News TCT 2021

iFR Matches FFR Through 5 Years: iFR-SWEDEHEART

November 04, 2021

Large Databases Hint at Sentinel Benefit During TAVR, but Uncertainty Remains

News Conference News TCT 2020

Large Databases Hint at Sentinel Benefit During TAVR, but Uncertainty Remains

October 16, 2020

MitraClip Pricey but ‘Acceptable’ in COAPT Cost-Efficacy Analysis

News Conference News TCT 2019

MitraClip Pricey but ‘Acceptable’ in COAPT Cost-Efficacy Analysis

September 29, 2019

COAPT Cost-Efficacy

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Four: Costs and Quality of Life Take Center Stage

September 29, 2019

NEOPRO: Two Next-Gen TAVR Valves Show Promise at 30 Days

News Conference News TCT 2018

NEOPRO: Two Next-Gen TAVR Valves Show Promise at 30 Days

Yael L. Maxwell

September 25, 2018

TALENT: Indian-Made Supraflex DES Stands Up Well Against Xience in All-Comers

News Conference News TCT 2018

TALENT: Indian-Made Supraflex DES Stands Up Well Against Xience in All-Comers

September 22, 2018

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

News Conference News TCT 2017

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

November 02, 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

October 30, 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

October 20, 2017

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

November 07, 2016

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

November 07, 2016

News Conference News TCT 2016

Cancer Patients Face Increased Risk of Acute MI, More PCI Complications, Higher Mortality, and Soaring Costs

Michael H. Wilson

October 31, 2016

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

ILUMIEN 3: OCT Imaging Matches IVUS but Fails To Beat Angiography for Stent Guidance in PCI

News Conference News TCT 2016

ILUMIEN III: OCT Imaging Matches IVUS but Fails to Beat Angiography for Stent Guidance in PCI

October 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.